Talphera Q2 net loss $3.8M; CMO Palmer retiring Oct 1, succeeded by Dr. Aslam

TALPHERA, INC.

Net loss $3.8M ($0.15 loss per share) vs $4.4M ($0.40 loss) in Q2 2023; cash $14.0M.
NEPHRO CRRT registrational study screening initiated; enrolling 166 patients at up to 14 U.S. sites.
Pamela Palmer, co-founder and CMO, to retire Oct 1; Dr. Shakil Aslam (current CDO) to become CMO.
Combined R&D and SG&A expenses rose to $4.3M from $4.2M year-over-year; no DSUVIA expenses.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Shakil Aslam

Chief Medical Officer

TLPH · TALPHERA, INC.

Effective: 2024-10-01
Filed: August 14, 2024, 7:59 PM ET

Upon Dr. Palmer’s retirement, Dr. Shakil Aslam, currently the Company’s Chief Development Officer, will assume the position of the Company’s Chief Medical Officer.

Departed

Pamela P. Palmer

Chief Medical Officer

TLPH · TALPHERA, INC.

Effective: 2024-10-01
Successor: Shakil Aslam
Filed: August 14, 2024, 7:59 PM ET

On August 12, 2024, Pamela P. Palmer, MD, PhD, the Company’s Chief Medical Officer and co-founder, notified the Company that she plans to retire and resign from the Company effective October 1, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Shakil Aslam was appointed as Chief Medical Officer at TALPHERA, INC..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

Upon Dr. Palmer’s retirement, Dr. Shakil Aslam, currently the Company’s Chief Development Officer, will assume the position of the Company’s Chief Medical Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Pamela P. Palmer resigned as Chief Medical Officer at TALPHERA, INC..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On August 12, 2024, Pamela P. Palmer, MD, PhD, the Company’s Chief Medical Officer and co-founder, notified the Company that she plans to retire and resign from the Company effective October 1, 2024.

View on SEC.gov

TALPHERA, INC. filing history →

Source: SEC EDGAR

accession 0001437749-24-026815

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.